https://www.statnews.com/2022/12/13/moderna-cancer-vaccine/ Skip to Main Content * * * * Community Try STAT+ TODAY STAT * Log In * Try STAT+ Today My Account * My Account * Billing * Log Out Try STAT+ My Account [ ] Search Cancel * TOPICS + Biotech + Business + Coronavirus + Health + Health Tech + Hospitals + In the Lab + Insurance + Pharma + Politics & Policy * OPINION + First Opinion + The Pharmalot View + Adam's Take + Matt's Take + Off the Charts * TEAM + Biotech & Pharma o Allison DeAngelis o Adam Feuerstein o Damian Garde o Matthew Herper o Meghana Keshavan o Kate Sheridan o Ed Silverman o Jonathan Wosen + Health Tech o Mario Aguilar o Katie Palmer o Mohana Ravindranath o Casey Ross + Business & Policy o Tara Bannow o Rachel Cohrs o Nicholas Florko o Bob Herman o Sarah Owermohle + Health & Science o Eric Boodman o Helen Branswell o Ambar Castillo o Angus Chen o Elizabeth Cooney o Isabella Cueto o Lev Facher o Theresa Gaffney o Olivia Goldhill o Andrew Joseph o Jason Mast o Megan Molteni o Usha Lee McFarling o Jennifer Adaeze Okwerekwu o Nicholas St. Fleur o Brittany Trang + Team o View All * EVENTS + Upcoming Industry Events + STAT Events + STAT Summits * PODCASTS + Color Code + First Opinion Podcast + The Readout LOUD * NEWSLETTERS * RESOURCES + STAT Trials Pulse + Reports + E-books * VIDEO * * STAT+ + STAT+ Exclusive analysis of biotech, pharma, and the life sciences Learn More o View Stories o My Account + Topics o Biotech o Pharma o Policy o Health Tech o Business + Columns o Adam's Take o Matt's Take o The Pharmalot View + Tools o CRISPR Trackr o Breakthrough Device Tracker o Drug Pricing Policy Cheat Sheet + Events o STAT+ Conversations o All STAT Events + Team o Biotech and Pharma o Health Tech o Politics and Policy o Health and Science Account * My Account * Billing * Subscribe * Log In * Help More * Community * Contribute * Group Subscriptions Follow Us * * * * * Trending: First Opinion Biotech Health STAT+ STAT+ Subscribe Now To access exclusive content, subscribe to STAT+ View Latest View the latest STAT+ stories [stat-plus-] In-depth analysis of biotech, pharma, and the life sciences * [journalism] Award-winning journalism from some of the nation's most trusted and well-connected reporters in the industry * [video-chat] Weekly live video chats with STAT+ reporters and leading industry experts in our STAT+ Conversations series * [events] Exclusive industry events hosted by STAT+, plus early-bird access and discounts to industry events around the country * [newsletter] Daily STAT+ newsletters get delivered to your inbox to brief you on the most important industry news of the day * [data-tools] Premium data tools like our CRISPR Trackr and Drug Pricing Policy Tracker Exclusive coverage and analysis of BIOTECH, PHARMA, AND THE LIFE SCIENCES Try STAT+ 30 days FREE Learn More [stat-plus-] In-depth analysis of biotech, pharma, and the life sciences * [journalism] Award-winning journalism from some of the nation's most trusted and well-connected reporters in the industry * [video-chat] Weekly live video chats with STAT+ reporters and leading industry experts in our STAT+ Conversations series * [events] Exclusive industry events hosted by STAT+, plus early-bird access and discounts to industry events around the country * [newsletter] Daily STAT+ newsletters get delivered to your inbox to brief you on the most important industry news of the day * [data-tools] Premium data tools like our CRISPR Trackr and Drug Pricing Policy Tracker Exclusive coverage and analysis of BIOTECH, PHARMA, AND THE LIFE SCIENCES Try STAT+ 30 days FREE Learn More [stat-plus-] * [journalism] Award-winning coverage from some of the nation's most trusted and well-connected journalists * [events] Exclusive live and virtual events hosted by STAT+, plus early access and discounts to can't-miss industry gatherings * [newsletter] Subscriber-only newsletters delivered to your inbox with the latest market-moving news and insights * [data-tools] Premium data tools that help you stay up to date with the latest research and developments * You've been selected! Try STAT+ 1 Month FREE Cancel Anytime [stat-plus-] * [journalism] Insights and exclusive stories on the technologies, personalities, power brokers, and political forces driving changes in life science * [events] STAT+ live events and webinars plus early access and discounts to industry gatherings * [newsletter] Subscriber-only newsletters delivered straight to your inbox with the latest industry news * [data-tools] Unlimited access to premium data tools that help you stay up to date with industry research and developments * You've been selected! Try STAT+ 1 month FREE Cancel Anytime Biotech STAT+ Moderna says cancer vaccine reduces melanoma's return by 44% * Matthew Herper By Matthew Herper Dec. 13, 2022 Reprints * * * * * * * * * blue sky moderna Ruby Wallau for STAT * * * * * * * * * An experimental cancer vaccine being developed by the biotechnology firm Moderna and the drug giant Merck reduced the risk that melanoma would return after surgery or that patients would die by 44%, the company said. The data, made public in a press release, represent the first evidence of an effective individualized cancer vaccine based on mRNA, the technology used in the Covid shots. [stat-plus-] Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED Log In * * * * * * * * * About the Author Reprints Matthew Herper Matthew Herper Senior Writer, Medicine, Editorial Director of Events Matthew covers medical innovation -- both its promise and its perils. [email protected] @matthewherper Tags biotechnology cancer pharmaceuticals Vaccines Create a display name to comment This name will appear with your comment [ ] There was an error saving your display name. Please check and try again. [Continue] Trending [] 'Out of control': Dozens of telehealth startups sent sensitive... 'Out of control': Dozens of telehealth startups sent sensitive health information to big tech companies [] Limits of 'Fauci effect': infectious disease applicants plummet, and... Limits of 'Fauci effect': infectious disease applicants plummet, and hospitals are scrambling [] New Biden changes to Obamacare coverage for generics splits... New Biden changes to Obamacare coverage for generics splits the industry Recommended [] Lawmakers tell Pfizer CEO to 'back off' on planned... Lawmakers tell Pfizer CEO to 'back off' on planned price hike for Covid-19 vaccine [] In bid to beat Bristol Myers, Takeda buys Nimbus'... In bid to beat Bristol Myers, Takeda buys Nimbus' anti-inflammatory drug for $4 billion [] Study points to new 'king on the block' for... Study points to new 'king on the block' for treatment of chronic lymphocytic leukemia Recommended Stories [328x185-00000000] Biotech Megan Molteni 'Make People Better': The CRISPR babies story you probably don't know, and how it was filmed in real-time [328x185-00000000] The Pharmalot View Ed Silverman Why a tone-deaf Regeneron executive deserved to be booed over Alzheimer's drug remarks advertisement [328x185-00000000] Health Elaine Chen Eli Lilly tightens access to diabetes drug, frustrating some people with obesity [328x185-00000000] Biotech Jason Mast 'If this works, it changes everything': Altos Labs founders lay out plan to reverse disease [328x185-00000000] Politics Nicholas Florko California bans flavored tobacco products, including vapes STAT Reporting from the frontiers of health and medicine Trending: * First Opinion * Biotech * Health * STAT+ * Coronavirus * Pharma Back to top Company * About STAT * Awards * Contact Us * Careers & Internships * Diversity & Inclusion * Licensing Stories * Our Team * Supporters Account * About STAT+ * FAQs * Log In * Subscribe App & Other Products * STAT App * Newsletters * Podcasts * STAT Madness * STAT Reports * STAT Trials Pulse * STAT Wunderkinds Group Subscriptions * Contact Us * Request A Quote Advertising * Advertise With Us Events * Upcoming Industry Events * STAT Events * STAT Summits * Sponsor An Event * Privacy * Comment Policy * Terms * Do Not Sell my Data * (c)2022 STAT * * * * * You've been selected! Subscribe to STAT+ for less than $2 per day You've been selected! STAT+ for less than $2/day Unlimited access to essential biotech, medicine, and life sciences journalism Start your free trial Subscribe to STAT+ for less than $2 per day Subscribe to STAT+ for less than $2 per day Unlimited access to the health care news and insights you need Get unlimited access * *